— Glynis Gebbens (@GlynisGebbens) September 16, 2015
And, on the subject of the flapper’s in a toilet, this tweet by Australian author Nick Whiting sums it up most succinctly:
The flapper is a simple object. A flat, flat object. That’s it.
The Flapper in a toilet in Sydney is an object that is flat, flat, flat. It is there to help make your bathroom feel less messy & it is there to serve as a distraction. If you can’t find a flapper in a toilet in Sydney, you can probably find one at the local fast food joint in your country which, like McDonald’s, is a little more civilized than McDonald’s.
Related: A Flapper in a Hot Tub
“If you don’t know anyone who wants to help you,” is a common excuse to not take action on a problem, says psychologist Susan Blackmore, author of the book “The Courage Under Pressure: Understanding Self-Esteem” and co-author of Why We Do What We Do (Penguin 2007).
Image copyright SPL Image caption The team wanted to make better diagnosis and treatment of patients who had problems using tablets for medical reasons
The UK and US researchers that pioneered the use of the ketamine-like drug Vysar – which treats psychiatric conditions – have revealed details of what they saw from patients who were treated in their own countries.
The US National Institute of Mental Health and the UK’s National Institute for Health Research said they had been able to improve the treatment rates with Vysar by almost 90%.
Vysar is used to treat mood and anxiety disorders.
It was developed to treat a number of psychiatric problems.
In the latest report, the researchers said there is now a “growing consensus that Vysar is a promising drug and an important addition to existing treatment options”.
They said that while not everyone who uses it will benefit, it can help improve recovery from serious conditions such as depression, bipolar disorder and schizophrenia.
Ketamine used
The US researchers, from the university system of the University at Buffalo in upstate New York, first became interested in Vysar after taking part in the 2009 study and reporting their findings.
Vysar was then developed with the help of the National Institute on Drug Abuse (NIDA) and the National Institute of Health (NIH), who said the